Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Seagen Inc.
M.D. Anderson Cancer Center
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
BeiGene
Columbia University
Northwestern University
City of Hope Medical Center
Wake Forest University Health Sciences
Stanford University
University of Nebraska
Hoffmann-La Roche
Eastern Cooperative Oncology Group
Columbia University
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
Northwestern University
Northwestern University
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Seagen Inc.
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
Mayo Clinic
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center